-
Eli Lilly Gears Up for a Busy Year with a Diversified Pipeline
Bio-IT World | Earlier this month at the J.P. Morgan Healthcare Conference, Eli Lilly Chairman and CEO David Ricks spoke at a fireside chat and presented what the company has planned for 2026, which also marks its 150th anniversary. This year is expected to be a productive one in terms of clinical trial activity, wider availability of medicines, and expansion into new therapeutic areas.
Jan 29, 2026
-
Follow the Money: Helicon Peptide Development, Next-Gen Obesity Metabolic Disease Therapies, Cell Stress Sensing Platform
Bio-IT World | Parabilis Medicines will continue the clinical development of FOG-001 (zolucatetide), the company’s lead investigational Helicon peptide; Alveus Therapeutics will advance into Phase 2 clinical development of ALV-100, the company’s lead program; Soley Therapeutics plans to advance its proprietary cell stress sensing platform; and more.
Jan 28, 2026
-
BigHat, Revvity Collaborate with Eli Lilly, Immunai Signs Agreement with Bristol Myers Squibb, SandboxAQ Launches New AI Model
Bio-IT World | BigHat Biosciences and Revvity have entered collaborations with Eli Lilly and Company; Immunai has signed an agreement with Bristol Myers Squibb; SandboxAQ launches a new AI model; and more.
Jan 27, 2026
-
Dealmakers Predict Banner Year as Biopharma M&A Momentum Builds
Bio-IT World | The mood at this year's J.P. Morgan Healthcare Conference signals a dramatic shift for biopharma dealmaking, with industry leaders projecting 2026 could eclipse last year's surging merger and acquisition activity. During an Endpoints News panel discussion, senior executives from AbbVie, Amgen, and Merck expressed confidence that favorable market conditions and breakthrough science are converging to create what one panelist called "a renaissance moment" for the sector.
Jan 23, 2026
-
Improved Drug Safety Needs Better Data Before AI
Bio-IT World | Applying artificial intelligence (AI) to fragmented and incomplete safety data cannot fill the gap left when the right information has not been captured during initial patient adverse event reporting. And yet, software vendors position the technology as a quick fix to safety data complexity. Although AI definitely has a role to play, it would be far better to use it to refine the data capture process.
Jan 23, 2026


